Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Police have also revealed security footage showing Justin Zelin falling from his balcony in February ...

April 13 (Reuters) - Alamar Biosciences and Kailera Therapeutics kicked off roadshows for their U.S. initial public offerings on Monday, aiming for billion-dollar-plus valuations as biotech companies ...

Gossamer Bio is picking up the pieces after failing to bring its only late-stage drug to market. The local biotech plans to ...

Seaport Therapeutics has filed to go public. The buzzy Boston biotech was founded by the same team behind the local success story Karuna Therapeutics, which was bought by Bristol Myers Squibb for $14 ...

This oncology-focused biotech, advancing multiple clinical-stage therapeutics, just reported a notable insider sale in recent ...

Commit matching funds to the KC BioHub’s next federal application. Develop targeted incentives that match Missouri’s. | Opinion ...

Alamar's IPO would be only the second Bay Area biotech offering this year, following a $381 million offering by ...

Revolution Medicines (RVMD) is one of the best stocks on Wall Street today after breakthrough cancer pill results ...

If Biotech manages to break out to new highs at some point this year, it would clear a significant resistance hurdle and open ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...